SG10201402148SA - Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate - Google Patents

Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Info

Publication number
SG10201402148SA
SG10201402148SA SG10201402148SA SG10201402148SA SG10201402148SA SG 10201402148S A SG10201402148S A SG 10201402148SA SG 10201402148S A SG10201402148S A SG 10201402148SA SG 10201402148S A SG10201402148S A SG 10201402148SA SG 10201402148S A SG10201402148S A SG 10201402148SA
Authority
SG
Singapore
Prior art keywords
hydroxycyclopentyl
inden
ylamino
pyrrolo
pyrimidin
Prior art date
Application number
SG10201402148SA
Other languages
English (en)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of SG10201402148SA publication Critical patent/SG10201402148SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201402148SA 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate SG10201402148SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21622109P 2009-05-14 2009-05-14

Publications (1)

Publication Number Publication Date
SG10201402148SA true SG10201402148SA (en) 2014-07-30

Family

ID=42396430

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201402148SA SG10201402148SA (en) 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
SG2011081957A SG175929A1 (en) 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011081957A SG175929A1 (en) 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Country Status (18)

Country Link
US (2) US9187482B2 (ja)
EP (2) EP3091020B1 (ja)
JP (3) JP2012526808A (ja)
KR (2) KR20120024715A (ja)
CN (2) CN104016987A (ja)
AU (1) AU2010248151B2 (ja)
BR (1) BRPI1012142A2 (ja)
CA (1) CA2761256C (ja)
IL (1) IL216201A (ja)
MX (1) MX2011012108A (ja)
NZ (2) NZ596470A (ja)
PE (2) PE20161222A1 (ja)
PH (1) PH12015501925A1 (ja)
RU (1) RU2562245C2 (ja)
SG (2) SG10201402148SA (ja)
UA (1) UA108986C2 (ja)
WO (1) WO2010132110A1 (ja)
ZA (1) ZA201108347B (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ES2758027T3 (es) 2007-08-02 2020-05-04 Millennium Pharm Inc Intermedios para la síntesis de inhibidores de enzimas activadoras de actividad E1
WO2010132110A1 (en) 2009-05-14 2010-11-18 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
JP2013541587A (ja) * 2010-11-05 2013-11-14 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎｅｄｄ８活性化酵素阻害剤の投与
BR112014004239A2 (pt) * 2011-08-24 2017-03-21 Millennium Pharm Inc inibidores de enzima ativadora de nedd8
CA2854461C (en) 2011-11-03 2021-01-19 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
BR112014020365B1 (pt) * 2012-02-17 2023-02-23 Takeda Pharmaceutical Company Limited Inibidores de pirazolopirimidinila de enzima de ativação de ubiquitina
CN104684559A (zh) * 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
WO2014055543A2 (en) * 2012-10-01 2014-04-10 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
US20160074404A1 (en) 2013-05-14 2016-03-17 Millennium Pharmaceutcals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
US9695154B2 (en) 2013-07-02 2017-07-04 Millennium Pharmaceuticals, Inc. Heteroaryl inhibitors of sumo activating enzyme
UY36198A (es) 2014-07-01 2016-01-29 Millennium Pharm Inc Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo
CN106008394B (zh) * 2016-05-23 2018-12-04 中国人民解放军第二军医大学 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途
JP2020534331A (ja) 2017-09-21 2020-11-26 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用
JP2022521972A (ja) * 2019-02-26 2022-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッド アジュバントとして有用な化合物
KR20210115680A (ko) 2020-03-16 2021-09-27 서희강 연설용 프롬프터
WO2022112951A1 (en) * 2020-11-25 2022-06-02 Takeda Pharmaceutical Company Limited Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622561A (en) 1969-08-18 1971-11-23 Univ Utah Nucleoside sugar esters of sulfamic acid and method for preparation of the same
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
JPS62108897A (ja) 1985-11-05 1987-05-20 Rikagaku Kenkyusho アスカマイシン誘導体及びその合成法並びに制癌剤
GB8813148D0 (en) 1988-06-03 1988-07-06 Glaxo Group Ltd Chemical compounds
GB8826205D0 (en) 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5470898A (en) 1993-06-30 1995-11-28 Montell North America Inc. Sorbitol derivatives as nucleators and clarifiers for polyolefins, and polyolefin compositions obtained therewith
GB9325809D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
GB9325810D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
US6210917B1 (en) 1993-12-29 2001-04-03 The Regents Of The University Of California Method for suppressing multiple drug resistance in cancer cells
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US5973161A (en) 1996-03-18 1999-10-26 The University Of North Carolina At Chapel Hill Enantioselective synthesis of cyclopentenes
US5824657A (en) 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US6734283B1 (en) 1997-12-19 2004-05-11 Millennium Pharmaceuticals, Inc. Human proteins responsible for NEDD8 activation and conjugation
JPH11228422A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
JPH11228446A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
EP1474147B1 (en) 2001-12-07 2010-05-05 Vertex Pharmaceuticals Incorporated Pyrimidine-based compounds useful as gsk-3 inhibitors
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7338957B2 (en) 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005037845A1 (en) 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
JP2007530445A (ja) 2004-03-30 2007-11-01 大正製薬株式会社 ピリミジン誘導体及びその使用に関連する治療方法
EP1758873A1 (en) 2004-06-22 2007-03-07 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
JP5048520B2 (ja) 2005-02-04 2012-10-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素の阻害剤
EP2402334B1 (en) 2006-02-02 2016-06-29 Millennium Pharmaceuticals, Inc. Inhibitors of E1 Activating Enzymes
MY157177A (en) 2006-08-08 2016-05-13 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of e1 activating enzymes
ES2758027T3 (es) * 2007-08-02 2020-05-04 Millennium Pharm Inc Intermedios para la síntesis de inhibidores de enzimas activadoras de actividad E1
WO2010132110A1 (en) 2009-05-14 2010-11-18 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
CA2854461C (en) 2011-11-03 2021-01-19 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
US20160074404A1 (en) 2013-05-14 2016-03-17 Millennium Pharmaceutcals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents

Also Published As

Publication number Publication date
KR20120024715A (ko) 2012-03-14
US10016427B2 (en) 2018-07-10
RU2011150826A (ru) 2013-06-20
SG175929A1 (en) 2011-12-29
AU2010248151A1 (en) 2011-12-01
PE20161222A1 (es) 2016-12-01
NZ621128A (en) 2015-08-28
WO2010132110A1 (en) 2010-11-18
IL216201A (en) 2015-11-30
CN104016987A (zh) 2014-09-03
US20170000792A9 (en) 2017-01-05
EP3091020B1 (en) 2020-12-30
PE20120907A1 (es) 2012-08-18
NZ596470A (en) 2014-04-30
US9187482B2 (en) 2015-11-17
EP3091020A3 (en) 2017-01-11
CA2761256C (en) 2021-01-05
JP2012526808A (ja) 2012-11-01
BRPI1012142A2 (pt) 2016-03-29
JP2015096547A (ja) 2015-05-21
EP3091020A2 (en) 2016-11-09
US20160030432A1 (en) 2016-02-04
UA108986C2 (uk) 2015-07-10
PH12015501925A1 (en) 2018-01-22
JP2017105816A (ja) 2017-06-15
AU2010248151B2 (en) 2016-07-14
ZA201108347B (en) 2014-05-26
IL216201A0 (en) 2012-01-31
EP2430026A1 (en) 2012-03-21
CN102421780A (zh) 2012-04-18
US20110021544A1 (en) 2011-01-27
CA2761256A1 (en) 2010-11-18
MX2011012108A (es) 2011-12-08
KR20170102381A (ko) 2017-09-08
RU2562245C2 (ru) 2015-09-10

Similar Documents

Publication Publication Date Title
IL216201A0 (en) Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
FIC20200039I1 (fi) Kefiderokoli valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa
IL259296B (en) Sodium salt of (r1,s2,r5)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
HK1143154A1 (en) Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors b[23-d]
IL193141A (en) Compounds including pyrrolo [2,3– d] pyrimidine 7 - yl and sulphamate, pharmaceuticals and their use
SMT201400153B (it) Composti di pirazolo[1,5-A]pirimidina sostuiti come inibitori della trk chinasi
IL208355A0 (en) Heterocyclic copmpounds as adenosine receptor antagonist
HK1160116A1 (en) Pyrrolo[2,3-d]pyrimidine compounds [23-d]
IL215298A0 (en) Useful pharmaceutical salts of 7[(3r,4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
IL210447A0 (en) Icotinib hydrochloride, synthesis, crystalline forms, drug combinations, and uses thereof
AP3521A (en) Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors
ZA201100437B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazine derivatives as met kinase inhibitors
EP2086949A4 (en) PROCESS FOR THE PREPARATION OF BENZOXAZINES
EP2445891A4 (en) 5-CHAIN HETEROARYL DERIVATIVES AS SPHINOSINE-1-PHOSPHATE RECEPTOR AGONISTS
IL206479A0 (en) Crystalline forms of palonosetron hydrochloride
GB0612508D0 (en) Crystalline duloxetine hydrochloride
GB0700830D0 (en) Crystalline duloxetine hydrochloride
GB0612506D0 (en) Crystalline duloxetine hydrochloride
PT1991548E (pt) Sal do antagonista de cd 80
IL194389A0 (en) Process for preparing heterocyclic derivatives
IL215521A0 (en) DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
ZA201105257B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyrimidine derivatives
ZA201000802B (en) Process for the preparation of alfuzosin hydrochloride
EP2511276A4 (en) PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE
AP2007003934A0 (en) Hydrochloride of 4-ÄÄ4-ÄÄ4-(2-cyanoethenyl)-2,6-dimethylphenylÜaminoÜ-2-pyrimidinylÜaminoÜbenzonitrile